Who We Are

 Virmira Biotechnologies, Inc. is focused on developing in vitro diagnostic (IVD) kits for cancer patients, specifically the detection of circulating tumor cells (CTCs) using liquid biopsies. The fundamental difference between traditional cancer diagnostic methods and liquid biopsy lies in the origin of the specimen used for diagnosis. For traditional diagnosis, where specimens come from surgery or biopsy of solid tumors, obtaining specimens can be difficult, and the number of times to obtain specimens is often limited, especially for visceral tumors. Liquid biopsy, especially the detection of circulating tumor cells, is considered the future of cancer diagnosis. Currently, however, only one CTC detection method, CellSearch^TM, has been approved by the FDA for clinical use. The technical limitations of current CTC detection methods may be a bottleneck in the clinical use of CTC detection.

 Virmira has successfully licensed the UniPro technology (patent number US 2021/0102946 A1 and CN 111727244 A) from the University of Houston (UH) to further develop it into a ready-to-use test kit for clinical use. UniPro is a unique and revolutionary CTC detection technology that offers many advantages over CellSearch^TM and other CTC detection methods currently in development. Virmira plans to develop the UniPro test for use in small clinical diagnostic laboratories and large chains of centralized diagnostic facilities. The company will lead prototype development, assemble easy-to-use test kits to test patient samples and seek FDA approval.